Accuray touts CyberKnife results in breast cancer radiation therapy

Accuray is highlighting clinical results that suggest that early-stage breas...Read more on AuntMinnie.comRelated Reading: Accuray reports revenue gains for Q1 Accuray to introduce Volo Ultra at ASTRO 2021 Accuray inks collaboration with C-RAD Accuray promotes prostate cancer research at ESTRO 2021 Accuray lands Radixact install in India
Source: Headlines - Category: Radiology Source Type: news

Related Links:

This study aims to investigate the long-term risk of a SPM attributable to the radiation therapy in patients with the initial lung cancer.METHODS: Patients initially diagnosed with lung cancer between January 1975 and November 2011 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. SPM was defined as the occurrence of a second cancer at least five years after the diagnosis of the initial lung cancer. Age- and propensity score matching (PSM)-adjusted competing risk analyses were performed to compare the risk of SPM.RESULTS: Of 47,911 patients, 9,162 (19.1%) underwent radiotherapy for the i...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Authors: Source Type: research
An approach for eliminating racial disparities in breast and lung cancer treatmen...Read more on AuntMinnie.comRelated Reading: Accuray touts CyberKnife results in breast cancer radiation therapy RefleXion to showcase tech, abstracts at ASTRO 2021 Black individuals may not benefit from wider lung screening guidance Regulatory complexity challenges radiology administrators Radiation therapy takes toll on prostate cancer patients' finances
Source: Headlines - Category: Radiology Source Type: news
Mol Biol Rep. 2021 Oct 20. doi: 10.1007/s11033-021-06752-9. Online ahead of print.ABSTRACTCancer immunotherapy is a rapidly evolving concept that has been given the tag "fifth pillar" of cancer therapy while radiation therapy, chemotherapy, surgery and targeted therapy remain the other four pillars. This involves the stimulation of the immune system to control tumor growth and it specifically targets the neoplastic cells rather than the normal cells. Conventional chemotherapy has many limitations which include drug resistance, recurrence of cancer and severe adverse effects. Immunology has made major treatment br...
Source: Molecular Biology Reports - Category: Molecular Biology Authors: Source Type: research
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also ...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
CONCLUSION: Spine SBRT at our institution showed a 2-year LC of 70.6%, without G3 toxicities. Delaying SBRT at least 6 months to administer systemic treatment was related to an improvement in local control.PMID:34342817 | DOI:10.1007/s12094-021-02684-9
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | India Health | Prostate Cancer | Radiation Therapy | Radiology